Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

FDA and Manufacturers Ponder Biosimilars Pathway

Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.
Jul 2, 2011

Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.

Safety Concerns and Shortages Challenge Pharma

Industry struggles to curb drug abuse, diversion, and disruptions in supply.
Jun 2, 2011

Industry struggles to curb drug abuse, diversion, and disruptions in supply.

Experts Ponder Ways to Fill Pharma Pipeline

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.
May 2, 2011

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.

Health-Reform Controversies

Courts and Congress seek to reshape policies and programs.
Apr 2, 2011

Courts and Congress seek to reshape policies and programs.

Drug Safety and Shortages Challenge Manufacturers

As drug shortages make headlines, FDA tests the Sentinel safety system and its efect on healthcare.
Mar 2, 2011

As drug shortages make headlines, FDA tests the Sentinel safety system and its efect on healthcare.

FDA Faces Internal Changes and Challenges

Food-safety, transparency, and counterfeit-drug growth will tax agency resources.
Feb 2, 2011

Food-safety, transparency, and counterfeit-drug growth will tax agency resources.

Cost and Compliance Dominate Agenda for 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.
Jan 2, 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.

Pharma Faces New Political Landscape

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.
Dec 2, 2010

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.

Comparative Research Poses Challenges

A new center may provide evidence for improving care, but could discourage coverage of treatments.
Nov 2, 2010

A new center may provide evidence for improving care, but could discourage coverage of treatments.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here